fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Tobramycin

All products: Limited Use (codes 472)

TOBI Podhaler · DIN 02365154 · 28 mg · Inh Pd-capsule

Limited Use, Reason for Use code 472 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 472 required
Write on scriptReason for Use code 472 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 472
Reason for Use code 472 For the management of cystic fibrosis patients with chronic pulmonary Pseudomonas aeruginosa (P. aeruginosa) infections. Tobramycin is administered in alternating periods of 28 days. After 28 days of therapy, patients should stop therapy for the next 28 days, and then resume therapy for the next 28 day on / 28 day off cycle. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
TOBI Podhaler · DIN 02365154 Manufacturer: BGP Pharma ULC; listing date 2016-06-29 Health Canada: Marketed since 2020-03-11 · brand TOBI PODHALER · ATC J01GB01 TOBRAMYCIN · form Capsule · route Inhalation · ingredients TOBRAMYCIN 28 MG · company Bgp pharma ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

TOBI Podhaler: Formulary list price $14.69 per unit (the source does not state the unit; exact figure $14.6911). What the ministry pays, not the patient.

Ministry pays: $14.6911 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02365154)

Source record
DIN 02365154: TOBI Podhaler Raw flags: sec12=Y, sec3=Y Item: 081228163; group id 50; item number 0107; lccId 00265; manufacturer id BGP Source form: Inh Pd-Cap; strength: 28mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $14.6911; ministry $14.6911 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02365154 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85000
Shortage status: resolved shortage (ended March 2, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02365154
Shortage record checked October 6, 2026

Other products in the same Health Canada class (J01GB): coverage varies; not interchangeable

  • Tobramycin (Nebcin): general benefit, not a benefit
Other drugs in the same formulary class (08:12:28 Other Antibiotics) and how they are covered

Matched class: 08:12:28 Other Antibiotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CEFIXIME, CLINDAMYCIN PALMITATE Some products covered without a code (check the product listing): CEFADROXIL, CEFPROZIL, CEFTRIAXONE DISODIUM, CEFUROXIME AXETIL, CEPHALEXIN MONOHYDRATE, CLINDAMYCIN HCL, TOBRAMYCIN SULFATE 08:12:28 Other Antibiotics

TOBRAMYCIN SULFATE

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: 80mg/2mL · Inj Sol-2mL Pk

CEFADROXIL

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: 500mg · Cap

CEFIXIME

· 4 products · General benefit · strengths: 20mg/mL, 400mg · Oral Susp, Tab

CEFPROZIL

· 17 products · General benefit (11), Listed, not a benefit (6) · strengths: 125mg/5mL, 250mg/5mL, 250mg, 500mg · Oral Susp-100mL Pk, Oral Susp-75mL Pk, Tab

CEFTRIAXONE DISODIUM

· 16 products · Listed, not a benefit (3), General benefit (9), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 0.25g/Vial, 1g/Vial, 2g/Vial, 10g/Vial · Inj Pd-Vial Pk

CEFUROXIME AXETIL

· 9 products · General benefit (7), Listed, not a benefit (2) · strengths: 125mg/5mL, 250mg, 500mg · Susp, Tab

CEPHALEXIN MONOHYDRATE

· 29 products · Listed, not a benefit (6), General benefit (23) · strengths: 250mg, 500mg, 25mg/mL, 50mg/mL · Cap, Pd for Oral Susp, Tab

CLINDAMYCIN HCL

· 22 products · Listed, not a benefit (2), General benefit (20) · strengths: 150mg, 300mg · Cap

CLINDAMYCIN PALMITATE

· 1 products · General benefit · strengths: 15mg/mL · Pd for Oral Susp

DALBAVANCIN HYDROCHLORIDE

· 1 products · Limited Use, codes 677 · strengths: 500mg/Vial · Pd for Sol (Preservative-Free)

RIFAXIMIN

· 1 products · Limited Use, codes 475 · strengths: 550mg · Tab

VANCOMYCIN HCL

· 4 products · Limited Use, codes 557, 558, 559, 560 (2), Off-Formulary Interchangeable, not an ODB benefit (2) · strengths: 125mg, 250mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 08:12:28 and 4 more
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:16 Penicillins, 08:12:24 Tetracyclines, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE TOBREX (Tobramycin Ophthalmic Solution, USP) and TOBREX (Tobramycin Ophthalmic Ointment, USP) are topical antibiotic preparations indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. Appropriate monitoring of bacterial response to topical antibiotic therapy should accompany the use of TOBREX. To reduce the development of drug-resistant bacteria and maintain the effectiveness of TOBREX and other antibacterial drugs, TOBREX should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. https://pdf.hres.ca/dpd_pm/00055025.PDF PM date: February 12, 2020 Source product: TOBREX; DIN 00513962; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.